Interdisciplinary Perspectives on Infectious Diseases
Volume 2010 (2010), Article ID 273573, 18 pages
doi:10.1155/2010/273573
Review Article

Chlamydophila pneumoniae Infection and Its Role in Neurological Disorders

Carlo Contini,1 Silva Seraceni,1 Rosario Cultrera,1 Massimiliano Castellazzi,2 Enrico Granieri,2 and Enrico Fainardi3

1Section of Infectious Diseases, Department of Clinical and Experimental Medicine, National Institute of Neuroscience and Neuroscience Center, University of Ferrara, Via Fossato di Mortara, 23, 44100 Ferrara, Italy
2Section of Neurology, Department of Medical and Surgical Sciences of the Communication and Behaviour, Multiple Sclerosis Center, National Institute of Neuroscience and Neuroscience Center, University of Ferrara, Arcispedale S. Anna, Corso della Giovecca 203, 44100 Ferrara, Italy
3Neuroradiology Unit, Department of Neurosciences and Rehabilitation, Azienda Ospedaliera-Universitaria, National Institute of Neuroscience and Neuroscience Center, University of Ferrara, Arcispedale S. Anna, Corso della Giovecca 203, 44100 Ferrara, Italy

Received 27 July 2009; Accepted 25 November 2009

Academic Editor: Guey Chuen Perng

Copyright © 2010 Carlo Contini et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. D. E. Everett, R. M. Bush, and A. A. Andersen, “Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms,” International Journal of Systematic Bacteriology, vol. 49, no. 2, pp. 415–440, 1999. View at Scopus
  2. P. Saikku, M. Leinonen, K. Mattila, et al., “Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction,” The Lancet, vol. 2, no. 8618, pp. 983–986, 1988. View at Scopus
  3. M. Kleemola, P. Saikku, R. Visakorpi, S. P. Wang, and J. T. Grayston, “Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland,” Journal of Infectious Diseases, vol. 157, no. 2, pp. 230–236, 1988. View at Scopus
  4. C.-C. Kuo, L. A. Jackson, L. A. Campbell, and J. T. Grayston, “Chlamydia pneumoniae (TWAR),” Clinical Microbiology Reviews, vol. 8, no. 4, pp. 451–461, 1995. View at Scopus
  5. C. H. Mordhorst, S. P. Wang, and J. T. Grayston, “Outbreak of Chlamydia pneumoniae infection in four farm families,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 11, no. 7, pp. 617–620, 1992. View at Scopus
  6. C. Yucesan and S. Sriram, “Chlamydia pneumoniae infection of the central nervous system,” Current Opinion in Neurology, vol. 14, no. 3, pp. 355–359, 2001. View at Publisher · View at Google Scholar · View at Scopus
  7. C. W. Stratton and S. Sriram, “Association of Chlamydia pneumoniae with central nervous system disease,” Microbes and Infection, vol. 5, no. 13, pp. 1249–1253, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. C. W. Stratton and W. M. Mitchell, “The immunopathology of chlamydial infections,” Antimicrobics and Infectious Diseases Newsletter, vol. 16, no. 12, pp. 89–94, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Ciervo, P. Visca, A. Petrucca, L. M. Biasucci, A. Maseri, and A. Cassone, “Antibodies to 60-kilodalton heat shock protein and outer membrane protein 2 of Chlamydia pneumoniae in patients with coronary heart disease,” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 1, pp. 66–74, 2002. View at Publisher · View at Google Scholar · View at Scopus
  10. O. S. Mahdi, B. D. Horne, K. Mullen, J. B. Muhlestein, and G. I. Byrne, “Serum immunoglobulin G antibodies to chlamydial heat shock protein 60 but not to human and bacterial homologs are associated with coronary artery disease,” Circulation, vol. 106, no. 13, pp. 1659–1663, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Leinonen and P. Saikku, “Evidence for infectious agents in cardiovascular disease and atherosclerosis,” Lancet Infectious Diseases, vol. 2, no. 1, pp. 11–17, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. L. A. Campbell and C.-C. Kuo, “Chlamydia pneumoniae: an infectious risk factor for atherosclerosis?” Nature Reviews Microbiology, vol. 2, no. 1, pp. 23–32, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. F. F. Mussa, H. Chai, X. Wang, Q. Yao, A. B. Lumsden, and C. Chen, “Chlamydia pneumoniae and vascular disease: an update,” Journal of Vascular Surgery, vol. 43, no. 6, pp. 1301–1307, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. A. Palikhe, M.-L. Lokki, P. Saikku, et al., “Association of Chlamydia pneumoniae infection with HLA-B∗35 in patients with coronary artery disease,” Clinical and Vaccine Immunology, vol. 15, no. 1, pp. 55–59, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  15. G. I. Byrne, “Chlamydia uncloaked,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 14, pp. 8040–8042, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. G. I. Byrne and D. M. Ojcius, “Chlamydia and apoptosis: life and death decisions of an intracellular pathogen,” Nature Reviews Microbiology, vol. 2, no. 10, pp. 802–808, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. J. Boman, S. Söderberg, J. Forsberg, et al., “High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors,” Journal of Infectious Diseases, vol. 178, no. 1, pp. 274–277, 1998. View at Scopus
  18. A. MacIntyre, R. Abramov, C. J. Hammond, et al., “Chlamydia pneumoniae infection promotes the transmigration of monocytes through human brain endothelial cells,” Journal of Neuroscience Research, vol. 71, no. 5, pp. 740–750, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. C. C. Kuo and L. A. Campbell, “Chlamydial infections of the cardiovascular system,” Frontiers in Bioscience, vol. 8, pp. e36–e43, 2003. View at Scopus
  20. R. W. Peeling, S.-P. Wang, J. T. Grayston, et al., “Chlamydia pneumoniae serology: interlaboratory variation in microimmunofluorescence assay results,” Journal of Infectious Diseases, vol. 181, no. 6, supplement 3, pp. S426–S429, 2000. View at Scopus
  21. P. Apfalter, “Chlamydia pneumoniae, stroke, and serological associations: anything learned from the atherosclerosis-cardiovascular literature or do we have to start over again?” Stroke, vol. 37, no. 3, pp. 756–758, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. N. Mackman, “Lipopolysaccharide induction of gene expression in human monocytic cells,” Immunologic Research, vol. 21, no. 2-3, pp. 247–251, 2000. View at Scopus
  23. M. V. Kalayoglu, L. Indrawati, R. P. Morrison, S. G. Morrison, Y. Yuan, and G. I. Byrne, “Chlamydial virulence determinants in atherogenesis: the role of chlamydial lipopolysaccharide and heat shock protein 60 in macrophage-lipoprotein interactions,” Journal of Infectious Diseases, vol. 181, no. 6, supplement 3, pp. S483–S489, 2000. View at Scopus
  24. I. W. Fong, B. Chiu, E. Viira, W. Tucker, H. Wood, and R. W. Peeling, “Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques,” Journal of Infectious Diseases, vol. 186, no. 10, pp. 1469–1473, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. T. Huittinen, M. Leinonen, L. Tenkanen, et al., “Autoimmunity to human heat shock protein 60, Chlamydia pneumoniae infection, and inflammation in predicting coronary risk,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 22, no. 3, pp. 431–437, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. M. L. J. Wimmer, R. Sandmann-Strupp, P. Saikku, and R. L. Haberl, “Association of chlamydial infection with cerebrovascular disease,” Stroke, vol. 27, no. 12, pp. 2207–2210, 1996. View at Scopus
  27. M. S. V. Elkind, I.-F. Lin, J. T. Grayston, and R. L. Sacco, “Chlamydia pneumoniae and the risk of first ischemic stroke: the Northern Manhattan Stroke Study,” Stroke, vol. 31, no. 7, pp. 1521–1525, 2000. View at Scopus
  28. B. Piechowski-Jóźwiak, A. Mickielewicz, Z. Gaciong, H. Berent, and H. Kwieciński, “Elevated levels of anti-Chlamydia pneumoniae IgA and IgG antibodies in young adults with ischemic stroke,” Acta Neurologica Scandinavica, vol. 116, no. 3, pp. 144–149, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. J. G. Madre, J. L. R. Garcia, R. C. Gonzalez, et al., “Association between seropositivity to Chlamydia pneumoniae and acute ischaemic stroke,” European Journal of Neurology, vol. 9, no. 3, pp. 303–306, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. M. S. V. Elkind, M. L. C. Tondella, D. R. Feikin, B. S. Fields, S. Homma, and M. R. Di Tullio, “Seropositivity to Chlamydia pneumoniae is associated with risk of first ischemic stroke,” Stroke, vol. 37, no. 3, pp. 790–795, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. P. U. Heuschmann, D. Neureiter, M. Gesslein, et al., “Association between infection with Helicobacter pylori and Chlamydia pneumoniae and risk of ischemic stroke subtypes: results from a population-based case-control study,” Stroke, vol. 32, no. 10, pp. 2253–2258, 2001. View at Scopus
  32. A. Anzini, A. Cassone, M. Rasura, et al., “Chlamydia pneumoniae infection in young stroke patients: a case-control study,” European Journal of Neurology, vol. 11, no. 5, pp. 321–327, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. A. Vink, M. Poppen, A. H. Schoneveld, et al., “Distribution of Chlamydia pneumoniae in the human arterial system and its relation to the local amount of atherosclerosis within the individual,” Circulation, vol. 103, no. 12, pp. 1613–1617, 2001. View at Scopus
  34. K. Numazaki and S. Chibar, “Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS,” Neurology, vol. 57, no. 4, p. 746, 2001. View at Scopus
  35. S. F. Dowell, R. W. Peeling, J. Boman, et al., “Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada),” Clinical Infectious Diseases, vol. 33, no. 4, pp. 492–502, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. J. Boman and M. R. Hammerschlag, “Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies,” Clinical Microbiology Reviews, vol. 15, no. 1, pp. 1–20, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. M. M. Ieven and V. Y. Hoymans, “Involvement of Chlamydia pneumoniae in atherosclerosis: more evidence for lack of evidence,” Journal of Clinical Microbiology, vol. 43, no. 1, pp. 19–24, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. A. J. Littman, L. A. Jackson, E. White, M. D. Thornquist, C. A. Gaydos, and T. L. Vaughan, “Interlaboratory reliability of microimmunofluorescence test for measurement of Chlamydia pneumoniae-specific immunoglobulin A and G antibody titers,” Clinical and Diagnostic Laboratory Immunology, vol. 11, no. 3, pp. 615–617, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. P. Maggi, R. Monno, A. Chirianni, et al., “Role of Chlamydia infection in the pathogenesis of atherosclerotic plaques in HIV-1-positive patients,” In Vivo, vol. 20, no. 3, pp. 409–414, 2006. View at Scopus
  40. G. Tositti, M. Rassu, P. Fabris, et al., “Chlamydia pneumoniae infection in HIV-positive patients: prevalence and relationship with lipid profile,” HIV Medicine, vol. 6, no. 1, pp. 27–32, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. V. Gaona-Flores, G. García-Elorriaga, M. Valerio-Minero, et al., “Anti-Chlamydophila pneumoniae antibodies as associated factor for carotoid atherosclerosis in patients wit AIDS,” Current HIV Research, vol. 6, no. 3, pp. 267–271, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. P. Apfalter, O. Assadian, F. Blasi, et al., “Reliability of nested PCR for detection of Chlamydia pneumoniae DNA in atheromas: results from a multicenter study applying standardized protocols,” Journal of Clinical Microbiology, vol. 40, no. 12, pp. 4428–4434, 2002. View at Publisher · View at Google Scholar · View at Scopus
  43. R. Sessa, M. Di Pietro, G. Schiavoni, et al., “Chlamydia pneumoniae DNA in patients with symptomatic carotid atherosclerotic disease,” Journal of Vascular Surgery, vol. 37, no. 5, pp. 1027–1031, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. A. Palikhe, T. Tiirola, M. Puolakkainen, et al., “Chlamydia pneumoniae DNA is present in peripheral blood mononuclear cells during acute coronary syndrome and correlates with chlamydial lipopolysaccharide levels in serum,” Scandinavian Journal of Infectious Diseases, vol. 41, no. 3, pp. 201–205, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. J. Gieffers, H. Füllgraf, J. Jahn, et al., “Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment,” Circulation, vol. 103, no. 3, pp. 351–356, 2001. View at Scopus
  46. J. Gieffers, J. Rupp, A. Gebert, W. Solbach, and M. Klinger, “First-choice antibiotics at subinhibitory concentrations induce persistence of Chlamydia pneumoniae,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 4, pp. 1402–1405, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. J. T. Grayston, R. A. Kronmal, L. A. Jackson, et al., “Azithromycin for the secondary prevention of coronary events,” The New England Journal of Medicine, vol. 352, no. 16, pp. 1637–1645, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. B. J. Balin, H. C. Gérard, E. J. Arking, et al., “Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain,” Medical Microbiology and Immunology, vol. 187, no. 1, pp. 23–42, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Nochlin, C. M. Shaw, L. A. Campbell, and C.-C. Kuo, “Failure to detect Chlamydia pneumoniae in brain tissues of Alzheimer's disease,” Neurology, vol. 53, no. 8, p. 1888, 1999.
  50. J. Gieffers, E. Reusche, W. Solbach, and M. Maass, “Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients,” Journal of Clinical Microbiology, vol. 38, no. 2, pp. 881–882, 2000.
  51. R. H. Ring and J. M. Lyons, “Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain,” Journal of Clinical Microbiology, vol. 38, no. 7, pp. 2591–2594, 2000.
  52. G. S. Taylor, I. B. Vipond, I. D. Paul, S. Matthews, G. K. Wilcock, and E. O. Caul, “Failure to correlate C. pneumoniae with late onset Alzheimer's disease,” Neurology, vol. 59, no. 1, pp. 142–143, 2002.
  53. M. A. Wozniak, A. Cookson, G. K. Wilcock, and R. F. Itzhaki, “Absence of Chlamydia pneumoniae in brain of vascular dementia patients,” Neurobiology of Aging, vol. 24, no. 6, pp. 761–765, 2003. View at Publisher · View at Google Scholar
  54. H. C. Gérard, U. Dreses-Werringloer, K. S. Wildt, et al., “Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain,” FEMS Immunology and Medical Microbiology, vol. 48, no. 3, pp. 355–366, 2006. View at Publisher · View at Google Scholar · View at PubMed
  55. B. J. Balin and D. M. Appelt, “Role of infection in Alzheimer's disease,” Journal of the American Osteopathic Association, vol. 101, no. 12, supplement 1, pp. S1–S6, 2001.
  56. R. W. Keefover, “The clinical epidemiology of Alzheimer's disease,” Neurologic Clinics, vol. 14, no. 2, pp. 337–351, 1996. View at Publisher · View at Google Scholar
  57. C. Kawas, S. Gray, R. Brookmeyer, J. Fozard, and A. Zonderman, “Age-specific incidence rates of Alzheimer's disease: the Baltimore Longitudinal Study of Aging,” Neurology, vol. 54, no. 11, pp. 2072–2077, 2000.
  58. A. Di Carlo, M. Baldereschi, L. Amaducci, et al., “Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA study,” Journal of the American Geriatrics Society, vol. 50, no. 1, pp. 41–48, 2002. View at Publisher · View at Google Scholar
  59. G. Ravaglia, P. Forti, F. Maioli, et al., “Incidence and etiology of dementia in a large elderly Italian population,” Neurology, vol. 64, no. 9, pp. 1525–1530, 2005. View at Publisher · View at Google Scholar · View at PubMed
  60. D. A. Evans, D. A. Bennett, R. S. Wilson, et al., “Incidence of Alzheimer disease in a biracial urban community: relation to apolipoprotein E allele status,” Archives of Neurology, vol. 60, no. 2, pp. 185–189, 2003. View at Publisher · View at Google Scholar
  61. R. Brookmeyer, S. Gray, and C. Kawas, “Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset,” American Journal of Public Health, vol. 88, no. 9, pp. 1337–1342, 1998.
  62. L.-F. Lue, L. Brachova, W. H. Civin, and J. Rogers, “Inflammation, Aβ deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration,” Journal of Neuropathology and Experimental Neurology, vol. 55, no. 10, pp. 1083–1088, 1996.
  63. R. F. Itzhaki, W.-R. Lin, D. Shang, G. K. Wilcock, B. Faragher, and G. A. Jamieson, “Herpes simplex virus type 1 in brain and risk of Alzheimer's disease,” The Lancet, vol. 349, no. 9047, pp. 241–244, 1997. View at Publisher · View at Google Scholar
  64. R. F. Itzhaki, C. B. Dobson, W.-R. Lin, and M. A. Wozniak, “Association of HSV1 and apolipoprotein E-ε4 in Alzheimer's disease,” Journal of NeuroVirology, vol. 7, no. 6, pp. 570–571, 2001. View at Publisher · View at Google Scholar
  65. B. G. T. Pogo, J. Casals, and T. S. Elizan, “A study of viral genomes and antigens in brains of patients with Alzheimer's disease,” Brain, vol. 110, no. 4, pp. 907–915, 1987.
  66. R. P. Friedland, C. May, and J. Dahlberg, “The viral hypothesis of Alzheimer's disease: absence of antibodies to lentiviruses,” Archives of Neurology, vol. 47, no. 2, pp. 177–178, 1990.
  67. E. B. Renvoize, I. O. Awad, and M. H. Hambling, “A sero-epidemiological study of conventional infectious agents in Alzheimer's disease,” Age and Ageing, vol. 16, no. 5, pp. 311–314, 1987.
  68. J. Miklossy, “Alzheimer's disease—a spirochetosis?” NeuroReport, vol. 4, no. 7, pp. 841–848, 1993.
  69. W. B. Matthews, “Unconventional virus infection and neurological disease,” Neuropathology and Applied Neurobiology, vol. 12, no. 2, pp. 111–116, 1986.
  70. S. R. Robinson, C. Dobson, and J. Lyons, “Challenges and directions for the pathogen hypothesis of Alzheimer's disease,” Neurobiology of Aging, vol. 25, no. 5, pp. 629–637, 2004. View at Publisher · View at Google Scholar · View at PubMed
  71. U. Dreses-Werringloer, M. Bhuiyan, Y. Zhao, H. C. Gérard, J. A. Whittum-Hudson, and A. P. Hudson, “Initial characterization of Chlamydophila (Chlamydia) pneumoniae cultured from the late-onset Alzheimer brain,” International Journal of Medical Microbiology, vol. 299, no. 3, pp. 187–201, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. H. C. Gérard, G. F. Wang, B. J. Balin, H. R. Schumacher, and A. P. Hudson, “Frequency of apolipoprotein E (APOE) allele types in patients with Chlamydia-associated arthritis and other arthritides,” Microbial Pathogenesis, vol. 26, no. 1, pp. 35–43, 1999. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. H. C. Gérard, K. L. Wildt, J. A. Whittum-Hudson, Z. Lai, J. Ager, and A. P. Hudson, “The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype,” Microbial Pathogenesis, vol. 39, no. 1-2, pp. 19–26, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  74. A. MacIntyre, C. J. Hammond, C. S. Little, D. M. Appelt, and B. J. Balin, “Chlamydia pneumoniae infection alters the junctional complex proteins of human brain microvascular endothelial cells,” FEMS Microbiology Letters, vol. 217, no. 2, pp. 167–172, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. C. S. Little, C. J. Hammond, A. MacIntyre, B. J. Balin, and D. M. Appelt, “Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice,” Neurobiology of Aging, vol. 25, no. 4, pp. 419–429, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. M. B. Loeb, D. W. Molloy, M. Smieja, et al., “A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease,” Journal of the American Geriatrics Society, vol. 52, no. 3, pp. 381–387, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. A. E. Finefrock, A. I. Bush, and P. M. Doraiswamy, “Current status of metals as therapeutic targets in Alzheimer's disease,” Journal of the American Geriatrics Society, vol. 51, no. 8, pp. 1143–1148, 2003. View at Publisher · View at Google Scholar · View at Scopus
  78. L. Cahoon, “The curious case of clioquinol,” Nature Medicine, vol. 15, no. 4, pp. 356–359, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. C. Contini, E. Fainardi, S. Seraceni, E. Granieri, M. Castellazzi, and R. Cultrera, “Molecular identification and antibody testing of Chlamydophila pneumoniae in a subgroup of patients with HIV-associated dementia complex. Preliminary results,” Journal of Neuroimmunology, vol. 136, no. 1-2, pp. 172–177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  80. S. Gartner, “HIV infection and dementia,” Science, vol. 287, no. 5453, pp. 602–604, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. G. Layh-Schmitt, C. Bendl, U. Hildt, et al., “Evidence for infection with Chlamydia pneumoniae in a subgroup of patients with multiple sclerosis,” Annals of Neurology, vol. 47, no. 5, pp. 652–655, 2000. View at Publisher · View at Google Scholar
  82. W. P. Li, X. Ming, S. Cook, B. Blumberg, and P. Dowling, “Chlamydia pneumoniae sequence frequently present in both MS and control spinal fluid,” Neurology, vol. 54, supplement 3, p. A165, 2000.
  83. J. Treib, A. Haaß, W. Stille, et al., “Multiple sclerosis and Chlamydia pneumoniae,” Annals of Neurology, vol. 47, no. 3, p. 408, 2000.
  84. J. Gieffers, D. Pohl, J. Treib, et al., “Presence of Chlamydia pneumoniae DNA in the cerebral spinal fluid is a common phenomenon in a variety of neurological diseases and not restricted to multiple sclerosis,” Annals of Neurology, vol. 49, no. 5, pp. 585–589, 2001. View at Publisher · View at Google Scholar
  85. S. Sotgiu, A. Piana, M. Pugliatti, et al., “Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis and neurological controls,” Multiple Sclerosis, vol. 7, no. 6, pp. 371–374, 2001. View at Publisher · View at Google Scholar
  86. H. Ikejima, S. Haranaga, H. Takemura, et al., “PCR-based method for isolation and detection of Chlamydia pneumoniae DNA in cerebrospinal fluids,” Clinical and Diagnostic Laboratory Immunology, vol. 8, no. 3, pp. 499–502, 2001. View at Publisher · View at Google Scholar · View at PubMed
  87. Q. Hao, N. Miyashita, M. Matsui, H.-Y. Wang, T. Matsushima, and T. Saida, “Chlamydia pneumoniae infection associated with enhanced MRI spinal lesions in multiple sclerosis,” Multiple Sclerosis, vol. 8, no. 5, pp. 436–440, 2002. View at Publisher · View at Google Scholar
  88. S. Chatzipanagiotou, C. Tsakanikas, M. Anagnostouli, M. Rentzos, A. Ioannidis, and C. Nicolaou, “Detection of Chlamydia pneumoniae in the cerebrospinal fluid of patients with multiple sclerosis by combination of cell culture and PCR. No evidence for possible association,” Molecular Diagnosis, vol. 7, no. 1, pp. 41–43, 2003. View at Publisher · View at Google Scholar
  89. L. M. E. Grimaldi, A. Pincherle, F. Martinelli-Boneschi, et al., “An MRI study of Chlamydia pneumoniae infection in Italian multiple sclerosis patients,” Multiple Sclerosis, vol. 9, no. 5, pp. 467–471, 2003. View at Publisher · View at Google Scholar
  90. K. Rostasy, H. Reiber, D. Pohl, et al., “Chlamydia pneumoniae in children with MS: frequency and quantity of intrathecal antibodies,” Neurology, vol. 61, no. 1, pp. 125–128, 2003.
  91. T. Dong-Si, J. Weber, Y. B. Liu, et al., “Increased prevalence of and gene transcription by Chlamydia pneumoniae in cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis,” Journal of Neurology, vol. 251, no. 5, pp. 542–547, 2004. View at Publisher · View at Google Scholar · View at PubMed
  92. C. Contini, R. Cultrera, S. Seraceni, M. Castellazzi, E. Granieri, and E. Fainardi, “Cerebrospinal fluid molecular demonstration of Chlamydia pneumoniae DNA is associated to clinical and brain magnetic resonance imaging activity in a subset of patients with relapsing-remitting multiple sclerosis,” Multiple Sclerosis, vol. 10, no. 4, pp. 360–369, 2004. View at Publisher · View at Google Scholar
  93. S. Sriram, A. Ljunggren-Rose, S.-Y. Yao, and W. O. Whetsell Jr., “Detection of chlamydial bodies and antigens in the central nervous system of patients with multiple sclerosis,” Journal of Infectious Diseases, vol. 192, no. 7, pp. 1219–1228, 2005. View at Publisher · View at Google Scholar · View at PubMed
  94. R. Sessa, G. Schiavoni, G. Borriello, et al., “Real time PCR for detection of Chlamydophila pneumoniae in peripheral blood mononuclear cells of patients with multiple sclerosis,” Journal of Neurology, vol. 254, no. 9, pp. 1293–1295, 2007. View at Publisher · View at Google Scholar · View at PubMed
  95. C. Contini, S. Seraceni, M. Castellazzi, E. Granieri, and E. Fainardi, “Chlamydophila pneumoniae DNA and mRNA transcript levels in peripheral blood mononuclear cells and cerebrospinal fluid of patients with multiple sclerosis,” Neuroscience Research, vol. 62, no. 1, pp. 58–61, 2008. View at Publisher · View at Google Scholar · View at PubMed
  96. Y.-W. Tang, S. Sriram, H. Li, et al., “Qualitative and quantitative detection of Chlamydophila pneumoniae DNA in cerebrospinal fluid from multiple sclerosis patients and controls,” PLoS ONE, vol. 4, no. 4, article e5200, 2009. View at Publisher · View at Google Scholar · View at PubMed
  97. D. W. Anderson, J. H. Ellenberg, C. M. Leventhal, S. C. Reingold, M. Rodriguez, and D. H. Silberberg, “Revised estimate of the prevalence of multiple sclerosis in the United States,” Annals of Neurology, vol. 31, no. 3, pp. 333–336, 1992.
  98. M. H. Barnett and I. Sutton, “The pathology of multiple sclerosis: a paradigm shift,” Current Opinion in Neurology, vol. 19, no. 3, pp. 242–247, 2006. View at Publisher · View at Google Scholar · View at PubMed
  99. J. W. Princeas, E. E. Kwon, E.-S. Cho, and L. R. Sharer, “Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques,” Annals of the New York Academy of Sciences, vol. 436, pp. 11–32, 1984.
  100. M. Bsibsi, R. Ravid, D. Gveric, and J. M. van Noort, “Broad expression of Toll-like receptors in the human central nervous system,” Journal of Neuropathology and Experimental Neurology, vol. 61, no. 11, pp. 1013–1021, 2002.
  101. A. G. Joyee and X. Yang, “Role of toll-like receptors in immune responses to chlamydial infections,” Current Pharmaceutical Design, vol. 14, no. 6, pp. 593–600, 2008. View at Publisher · View at Google Scholar
  102. S. Seraceni, L. Badia, A. Grilli, E. Fainardi, and C. Contini, “Role of toll like receptors in patients with multiple sclerosis and Chlamydophila pneumoniae infection,” in Proceedings of the European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 2009, abstract no. R2174.
  103. D. H. Gilden, “Infectious causes of multiple sclerosis,” Lancet Neurology, vol. 4, no. 3, pp. 195–202, 2005. View at Publisher · View at Google Scholar · View at PubMed
  104. I. Steiner, P. Nisipianu, and I. Wirguin, “Infection and the etiology and pathogenesis of multiple sclerosis,” Current Neurology and Neuroscience Reports, vol. 1, no. 3, pp. 271–276, 2001. View at Publisher · View at Google Scholar
  105. D. H. Gilden, “Chlamydia: a role for multiple sclerosis or more confusion,” Annals of Neurology, vol. 46, no. 1, pp. 4–5, 1999. View at Publisher · View at Google Scholar
  106. S. Sriram, W. Mitchell, and C. Stratton, “Multiple sclerosis associated with Chlamydia pneumoniae infection of the CNS,” Neurology, vol. 50, no. 2, pp. 571–572, 1998.
  107. S. Sriram, C. W. Stratton, S.-Y. Yao, et al., “Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis,” Annals of Neurology, vol. 46, no. 1, pp. 6–14, 1999. View at Publisher · View at Google Scholar
  108. C. W. Stratton and D. B. Wheldon, “Multiple sclerosis: an infectious syndrome involving Chlamydophila pneumoniae,” Trends in Microbiology, vol. 14, no. 11, pp. 474–479, 2006. View at Publisher · View at Google Scholar · View at PubMed
  109. E. Fainardi, M. Castellazzi, S. Seraceni, E. Granieri, and C. Contini, “Under the microscope: focus on Chlamydia pneumoniae infection and multiple sclerosis,” Current Neurovascular Research, vol. 5, no. 1, pp. 60–70, 2008. View at Publisher · View at Google Scholar
  110. K. L. Munger, R. W. Peeling, M. A. Hernán, et al., “Infection with Chlamydia pneumoniae and risk of multiple sclerosis,” Epidemiology, vol. 14, no. 2, pp. 141–147, 2003. View at Publisher · View at Google Scholar
  111. K. L. Munger, G. N. DeLorenze, L. I. Levin, et al., “A prospective study of Chlamydia pneumoniae infection and risk of MS in two US cohorts,” Neurology, vol. 62, no. 10, pp. 1799–1803, 2004.
  112. D. Buljevac, R. P. Verkooyen, B. C. Jacobs, et al., “Chlamydia pneumoniae and the risk for exacerbation in multiple sclerosis patients,” Annals of Neurology, vol. 54, no. 6, pp. 828–831, 2003. View at Publisher · View at Google Scholar · View at PubMed
  113. M. R. Hammerschlag, Z. Ke, F. Lu, P. Roblin, J. Boman, and B. Kalman, “Is Chlamydia pneumoniae present in brain lesions of patients with multiple sclerosis?” Journal of Clinical Microbiology, vol. 38, no. 11, pp. 4274–4276, 2000.
  114. J. Boman, P. M. Roblin, P. Sundström, M. Sandström, and M. R. Hammerschlag, “Failure to detect Chlamydia pneumoniae in the central nervous system of patients with MS,” Neurology, vol. 54, no. 1, p. 265, 2000.
  115. S. D. Poland and G. P. A. Rice, “Chlamydia pneumoniae and multiple sclerosis,” Neurology, vol. 54, supplement 3, p. A165, 2000.
  116. S. J. Furrows, J. C. Hartley, J. Bell, et al., “Chlamydophila pneumoniae infection of the central nervous system in patients with multiple sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 1, pp. 152–154, 2004.
  117. F. Cirino, W. C. Webley, C. West, N. L. Croteau, C. Andrezejewski Jr., and E. S. Stuart, “Detection of Chlamydia in the peripheral blood cells of normal donors using in vitro culture, immunofluorescence microscopy and flow cytometry techniques,” BMC Infectious Diseases, vol. 6, article 23, 2006. View at Publisher · View at Google Scholar · View at PubMed
  118. Y. Yamamoto, “PCR in diagnosis of infection: detection of bacteria in cerebrospinal fluids,” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 3, pp. 508–514, 2002. View at Publisher · View at Google Scholar
  119. J. B. Mahony, S. Chong, B. K. Coombes, M. Smieja, and A. Petrich, “Analytical sensitivity, reproducibility of results, and clinical performance of five PCR assays for detecting Chlamydia pneumoniae DNA in peripheral blood mononuclear cells,” Journal of Clinical Microbiology, vol. 38, no. 7, pp. 2622–2627, 2000.
  120. M. Kaufman, C. A. Gaydos, S. Sriram, J. Boman, M. L. Tondella, and H. J. Norton, “Is Chlamydia pneumoniae found in spinal fluid samples from multiple sclerosis patients? Conflicting results,” Multiple Sclerosis, vol. 8, no. 4, pp. 289–294, 2002. View at Publisher · View at Google Scholar
  121. S. Sriram, S.-Y. Yao, C. Stratton, et al., “Comparative study of the presence of Chlamydia pneumoniae in cerebrospinal fluid of patients with clinically definite and monosymptomatic multiple sclerosis,” Clinical and Diagnostic Laboratory Immunology, vol. 9, no. 6, pp. 1332–1337, 2002. View at Publisher · View at Google Scholar
  122. A. Saiz, M. A. Marcos, F. Graus, J. Vidal, and M. T. Jimenez de Anta, “No evidence of CNS infection with Chlamydia pneumoniae in patients with multiple sclerosis,” Journal of Neurology, vol. 248, no. 7, pp. 617–618, 2001. View at Publisher · View at Google Scholar
  123. T. Derfuss, R. Gürkov, F. T. Bergh, et al., “Intrathecal antibody production against Chlamydia pneumoniae in multiple sclerosis is part of a polyspecific immune response,” Brain, vol. 124, no. 7, pp. 1325–1335, 2001.
  124. F. Budak, S. Keçeli, H. Efendi, F. Budak, and H. Vahaboǧlu, “The investigation of Chlamydophila pneumoniae in patients with multiple sclerosis,” International Journal of Neuroscience, vol. 117, no. 3, pp. 409–415, 2007. View at Publisher · View at Google Scholar · View at PubMed
  125. S. A. Morré, C. J. A. de Groot, J. Killestein, et al., “Is Chlamydia pneumoniae present in the central nervous system of multiple sclerosis patients?” Annals of Neurology, vol. 48, no. 3, p. 399, 2000.
  126. E. Pucci, C. Taus, E. Cartechini, et al., “Lack of Chlamydia infection of the central nervous system in multiple sclerosis,” Annals of Neurology, vol. 48, no. 3, pp. 399–400, 2000.
  127. E. J. Thompson and M. S. Freedman, “Cerebrospinal fluid analysis in the diagnosis of multiple sclerosis,” Advances in Neurology, vol. 98, pp. 147–160, 2006.
  128. T. Smith-Jensen, M. P. Burgoon, J. Anthony, H. Kraus, D. H. Gilden, and G. P. Owens, “Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response,” Neurology, vol. 54, no. 6, pp. 1227–1232, 2000.
  129. D. Krametter, G. Niederwieser, A. Berghold, et al., “Chlamydia pneumoniae in multiple sclerosis: humoral immune responses in serum and cerebrospinal fluid and correlation with disease activity marker,” Multiple Sclerosis, vol. 7, no. 1, pp. 13–18, 2001. View at Publisher · View at Google Scholar
  130. D. Franciotta, E. Zardini, R. Bergamaschi, L. M. Grimaldi, L. Andreoni, and V. Cosi, “Analysis of Chlamydia pneumoniae-specific oligoclonal bands in multiple sclerosis and other neurologic diseases,” Acta Neurologica Scandinavica, vol. 112, no. 4, pp. 238–241, 2005. View at Publisher · View at Google Scholar · View at PubMed
  131. E. Fainardi, M. Castellazzi, I. Casetta, et al., “Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms,” Journal of the Neurological Sciences, vol. 217, no. 2, pp. 181–188, 2004. View at Publisher · View at Google Scholar
  132. P. G. Bagos, G. Nikolopoulos, and A. Ioannidis, “Chlamydia pneumoniae infection and the risk of multiple sclerosis: a meta-analysis,” Multiple Sclerosis, vol. 12, no. 4, pp. 397–411, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. L. M. Metz, Y. Zhang, M. Yeung, et al., “Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis,” Annals of Neurology, vol. 55, no. 5, p. 756, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. S. Sriram, S. Y. Yao, C. Stratton, H. Moses, P. A. Narayana, and J. S. Wolinsky, “Pilot study to examine the effect of antibiotic therapy on MRI outcomes in RRMS,” Journal of the Neurological Sciences, vol. 234, no. 1-2, pp. 87–91, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. C. W. Stratton and D. B. Wheldon, “Antimicrobial treatment of multiple sclerosis,” Infection, vol. 35, no. 5, pp. 383–385, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  136. C. Contini, “International conference on chlamydial and Mycoplasma human infections,” Future Microbiology, vol. 2, no. 4, pp. 373–376, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  137. C. Contini, S. Seraceni, R. Cultrera, M. Castellazzi, E. Granieri, and E. Fainardi, “Molecular detection of Parachlamydia-like organisms in cerebrospinal fluid of patients with multiple sclerosis,” Multiple Sclerosis, vol. 14, no. 4, pp. 564–566, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  138. D. H. Gilden, M. E. Devlin, M. P. Burgoon, and G. P. Owens, “The search for virus in multiple sclerosis brain,” Multiple Sclerosis, vol. 2, no. 4, pp. 179–183, 1996. View at Scopus
  139. R. Álvarez-Lafuente, V. De las Heras, M. Bartolomé, J. J. Picazo, and R. Arroyo, “Relapsing-remitting multiple sclerosis and human herpesvirus 6 active infection,” Archives of Neurology, vol. 61, no. 10, pp. 1523–1527, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. F. G. A. Moore and C. Wolfson, “Human herpes virus 6 and multiple sclerosis,” Acta Neurologica Scandinavica, vol. 106, no. 2, pp. 63–83, 2002. View at Publisher · View at Google Scholar · View at Scopus
  141. T. Christensen, “The role of EBV in MS pathogenesis,” International MS Journal, vol. 13, no. 2, pp. 52–57, 2006. View at Scopus
  142. D. Clark, “Human herpesvirus type 6 and multiple sclerosis,” Herpes, vol. 11, supplement 2, pp. 112A–119A, 2004. View at Scopus
  143. G. N. DeLorenze, K. L. Munger, E. T. Lennette, N. Orentreich, J. H. Vogelman, and A. Ascherio, “Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up,” Archives of Neurology, vol. 63, no. 6, pp. 839–844, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  144. P. Höllsberg, M. Kusk, E. Bech, H. J. Hansen, J. Jakobsen, and S. Haahr, “Presence of Epstein-Barr virus and human herpesvirus 6B DNA in multiple sclerosis patients: associations with disease activity,” Acta Neurologica Scandinavica, vol. 112, no. 6, pp. 395–402, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  145. J. M. van Noort, J. J. Bajramovic, A. C. Plomp, and M. J. B. van Stipdonk, “Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis,” Journal of Neuroimmunology, vol. 105, no. 1, pp. 46–57, 2000. View at Publisher · View at Google Scholar · View at Scopus
  146. S. Cepok, D. Zhou, R. Srivastava, et al., “Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1352–1360, 2005. View at Publisher · View at Google Scholar · View at Scopus
  147. A. Dolei, “MSRV/HERV-W/syncytin and its linkage to multiple sclerosis: the usability and the hazard of a human endogenous retrovirus,” Journal of NeuroVirology, vol. 11, no. 2, pp. 232–235, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  148. A. Fryden, E. Kihlstrom, R. Maller, K. Persson, V. Romanus, and S. Ansehn, “A clinical and epidemiological study of “ornithosis” caused by Chlamydia psittaci and Chlamydia pneumoniae (strain TWAR),” Scandinavian Journal of Infectious Diseases, vol. 21, no. 6, pp. 681–691, 1989. View at Scopus
  149. S. Haidl, S. Ivarsson, I. Bjerre, and K. Persson, “Guillain-Barré syndrome after Chlamydia pneumoniae infection,” The New England Journal of Medicine, vol. 326, no. 8, pp. 576–577, 1992. View at Scopus
  150. D. Michel, J. C. Antoine, B. Pozzetto, O. G. Gaudin, and F. Lucht, “Lumbosacral meningoradiculitis associated with Chlamydia pneumoniae infection,” Journal of Neurology Neurosurgery and Psychiatry, vol. 55, no. 6, p. 511, 1992. View at Scopus
  151. B. Sundelöf, H. Gnarpe, and J. Gnarpe, “An unusual manifestation of Chlamydia pneumoniae infection: meningitis, hepatitis, iritis and atypical erythema nodosum,” Scandinavian Journal of Infectious Diseases, vol. 25, no. 2, pp. 259–261, 1993. View at Scopus
  152. M. Socan, B. Beovic, and D. Kese, “Chlamydia pneumonia and meningoencephalitis,” The New England Journal of Medicine, vol. 331, no. 6, p. 406, 1994. View at Publisher · View at Google Scholar · View at Scopus
  153. M. Koskiniemi, M. Korppi, K. Mustonen, et al., “Epidemiology of encephalitis in children. A prospective multicentre study,” European Journal of Pediatrics, vol. 156, no. 7, pp. 541–545, 1997. View at Publisher · View at Google Scholar · View at Scopus
  154. T. M. Korman, J. D. Turnidge, and M. L. Grayson, “Neurological complications of chlamydial infections: case report and review,” Clinical Infectious Diseases, vol. 25, no. 4, pp. 847–851, 1997. View at Scopus
  155. A. Heick and E. Skriver, “Chlamydia pneumoniae-associated ADEM,” European Journal of Neurology, vol. 7, no. 4, pp. 435–438, 2000. View at Publisher · View at Google Scholar · View at Scopus
  156. J. Guglielminotti, N. Lellouche, E. Maury, M. Alzieu, B. Guidet, and G. Offenstadt, “Severe meningoencephalitis: an unusual manifestation of Chlamydia pneumoniae infection,” Clinical Infectious Diseases, vol. 30, no. 1, pp. 209–210, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  157. E. Anton, A. Otegui, and A. Alonso, “Meningoencephalitis and Chlamydia pneumoniae infection,” European Journal of Neurology, vol. 7, no. 5, p. 586, 2000. View at Publisher · View at Google Scholar · View at Scopus
  158. L. Airas, P. Kotilainen, R. Vainionpää, and R. J. Marttila, “Encephalitis associated with Chlamydia pneumoniae,” Neurology, vol. 56, no. 12, pp. 1778–1779, 2001. View at Scopus
  159. C. Boschin-Crinquette, A. Kreisler, L. Legout, P. Charpentier, A. Destée, and L. Defebvre, “Can meningoencephalitis be caused by Chlamydiae pneumoniae?” Revue Neurologique, vol. 161, no. 10, pp. 979–983, 2005. View at Scopus
  160. L. Wing, S. R. Leekam, S. J. Libby, J. Gould, and M. Larcombe, “The diagnostic interview for social and communication disorders: background, inter-rater reliability and clinical use,” Journal of Child Psychology and Psychiatry and Allied Disciplines, vol. 43, no. 3, pp. 307–325, 2002. View at Publisher · View at Google Scholar · View at Scopus
  161. S. E. Folstein and B. Rosen-Sheidley, “Genetics of autism: complex aetiology for a heterogeneous disorder,” Nature Reviews Genetics, vol. 2, no. 12, pp. 943–955, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  162. J. Veenstra-vanderweele, E. H. Cook Jr., and P. J. Lombroso, “Genetics of childhood disorders: XLVI. Autism, part 5: genetics of autism,” Journal of the American Academy of Child and Adolescent Psychiatry, vol. 42, no. 1, pp. 116–118, 2003. View at Scopus
  163. H. Takahashi, S. Arai, K. Tanaka-Taya, and N. Okabe, “Autism and infection/immunization episodes in Japan,” Japanese Journal of Infectious Diseases, vol. 54, no. 2, pp. 78–79, 2001. View at Scopus
  164. Y. Yamashita, C. Fujimoto, E. Nakajima, T. Isagai, and T. Matsuishi, “Possible association between congenital cytomegalovirus infection and autistic disorder,” Journal of Autism and Developmental Disorders, vol. 33, no. 4, pp. 455–459, 2003. View at Publisher · View at Google Scholar · View at Scopus
  165. J. E. Libbey, T. L. Sweeten, W. M. McMahon, and R. S. Fujinami, “Autistic disorder and viral infections,” Journal of NeuroVirology, vol. 11, no. 1, pp. 1–10, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  166. D. H. Thornton, “A survey of mycoplasma detection in veterinary vaccines,” Vaccine, vol. 4, no. 4, pp. 237–240, 1986. View at Scopus
  167. J. K. S. Chia and L. Y. Chia, “Chronic Chlamydia pneumoniae infection: a treatable cause of chronic fatigue syndrome,” Clinical Infectious Diseases, vol. 29, no. 2, pp. 452–453, 1999. View at Scopus
  168. R. Nicolson and P. Szatmari, “Genetic and neurodevelopmental influences in autistic disorder,” Canadian Journal of Psychiatry, vol. 48, no. 8, pp. 526–537, 2003. View at Scopus
  169. W. Huang, D. See, and J. Tiles, “The prevalence of Mycoplasma incognitus in the peripheral blood mononuclear cells of normal controls or patients with AIDS or chronic fatigue syndrome,” Journal of Clinical Microbiology, vol. 231, pp. 457–467, 1998.
  170. J. Nijs, G. L. Nicolson, P. De Becker, D. Coomans, and K. De Meirleir, “High prevalence of Mycoplasma infections among European chronic fatigue syndrome patients. Examination of four Mycoplasma species in blood of chronic fatigue syndrome patients,” FEMS Immunology and Medical Microbiology, vol. 34, no. 3, pp. 209–214, 2002. View at Publisher · View at Google Scholar · View at Scopus
  171. G. L. Nicolson, R. Gan, and J. Haier, “Multiple co-infections (Mycoplasma, Chlamydia, human herpes virus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms,” APMIS: Acta Pathologica, Microbiologica et Immunologica Scandinavica, vol. 111, no. 5, pp. 557–566, 2003. View at Publisher · View at Google Scholar · View at Scopus
  172. G. L. Nicolson, “Chronic bacterial and viral infections in neurodegenerative and neurobehavioral diseases,” Laboratory Medicine, vol. 39, no. 5, pp. 291–299, 2008. View at Publisher · View at Google Scholar · View at Scopus
  173. G. Campadelli-Fiume, P. Mirandola, and L. Menotti, “Human herpesvirus 6: an emerging pathogen,” Emerging Infectious Diseases, vol. 5, no. 3, pp. 353–366, 1999.
  174. D. Keen and S. Ward, “Austistic spectrum disorder: a child population profile,” Autism, vol. 8, no. 1, pp. 39–48, 2004. View at Publisher · View at Google Scholar · View at PubMed
  175. B. Fellerhoff, B. Laumbacher, and R. Wank, “High risk of schizophrenia and other mental disorders associated with chlamydial infections: hypothesis to combine drug treatment and adoptive immunotherapy,” Medical Hypotheses, vol. 65, no. 2, pp. 243–252, 2005. View at Publisher · View at Google Scholar · View at PubMed